Robbins LLP is Investigating Allegations that Hims & Hers Health, Inc. (HIMS) Deceptively Promoted and Sold Illegitimate Versions of Wegovy®

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025. Hims operates a telehealth platform that connects consumers to licensed healthcare professionals.

The Allegations

According to the complaint, on April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform.”  However, on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, “based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.” On this news, the Company’s share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.

Plaintiff alleges that during the class period, defendants failed to disclose to investors: (1) that Hims was engaged in the “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;” and (2) that, as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.

What Now: You may be eligible to participate in the class action against Hims & Hers Health, Inc.  Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 25, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.